A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects.
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2014
At a glance
- Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Pharmacokinetics; Therapeutic Use
- 31 Aug 2012 Status changed from recruiting to completed as reported by UKCRN.
- 18 Aug 2012 Planned End Date changed from 1 May 2012 to 31 Aug 2012 as reported by UKCRN.
- 18 Mar 2012 United Kingdom Clinical Research Network reports accrual to date changed from 60% to 80%.